Successful Treatment of Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Immunodeficiency With Extended Nirmatrelvir/Ritonavir: Case Series.

Autor:	Breeden M; Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA., Aitken SL; Department of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.; Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan, USA., Baang JH; Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA., Gravelin M; Michigan Institute for Clinical and Health Research, University of Michigan, Ann Arbor, Michigan, USA., Kaul DR; Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA., Lauring AS; Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA., Petty LA; Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA., Gregg KS; Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Jazyk:	angličtina
Zdroj:	Open forum infectious diseases [Open Forum Infect Dis] 2023 Apr 06; Vol. 10 (4), pp. ofad189. Date of Electronic Publication: 2023 Apr 06 (Print Publication: 2023).
DOI:	10.1093/ofid/ofad189
Abstrakt:	Immunocompromised patients with B-cell deficiencies are at risk for prolonged symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We describe 4 patients treated for B-cell malignancies with B-cell-depleting therapies who developed persistent SARS-CoV-2 infection and had resolution of symptoms following an extended course of nirmatrelvir/ritonavir. Competing Interests: Potential conflicts of interest. S. L. A. serves on an AstraZeneca advisory board. D. R. K. is a funded investigator for Gilead, AstraZeneca, Janssen, Nobelpharma, and Takeda. A. S. L. receives fees from Roche for service on steering committee for study of influenza antivirals. K. S. G. is principal investigator on trials for Pfizer and Ansun Pharmaceuticals. All other authors report no potential conflicts. (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu